Aflibercept/Rinucumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAflibercept/Rinucumab
Drug Alias NameEylea/rinucumabEylea/REGN-2176Rinucumab/AfliberceptAflibercept+RinucumabAflibercept/REGN-2176 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsYes Aflibercept
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals IncBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegeneron Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsWet age-related macular degenerationMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A